ECLIPSE Trial: Ensure’s Vascular Closure Device Speeds Hemostasis S. Chiu Wong MD Director, Cardiac Catheterization Laboratories New York Presbyterian.

Slides:

Advertisements

Similar presentations

ECLIPSE Trial: Ensure’s Vascular Closure Device Speeds Hemostasis

Advertisements

GUSTO-IV AMI G lobal U se of S trategies T o Open O ccluded Coronary Arteries in AMI.

Percutaneous Therapy of Pulmonic and Mitral Valve Disease Atman P. Shah MD FACC FSCAI Director, Coronary Care Unit Assistant Professor of Medicine The.

Stone p2203/Abstract/ Conclusions

Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by.

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.

Protecting Against Stroke

Access Site Complications Nick Cheshire MD FRCS, Professor of Vascular Surgery Imperial College Healthcare St Mary’s Hospital Campus.

An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48 Influence of Timing of Clopidogrel Treatment on the Efficacy and Safety of Bivalirudin.

ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc

Coronary Artery Disease: Diagnosis and Treatment

PCI VS CABG JOURNAL REVIEW

Molina Allen This presentation was prepared for COHP 450, Section VL1, taught by Dr. Njoku.

DuraSealTM Dural Sealant System PMA P040034

Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.

VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.

DHHS / FDA / CDRH 1 Circulatory Support Devices Panel Tuesday, September 11, 2001 CoSeal® Surgical Sealant P

Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis Dr. Quan, Dr. Mirhashemi, Dr. Chiang N Engl J Med 2006; 355:

A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.

TRI vs TFI in STEMI Shenyang Northern Hospital Wang Shouli Han Yalin.

Use of Arteriotomy Closure Devices and the Risk of Vascular Complications: An Analysis of 227,879 Patients in the NCDR Sameer K. Mehta MD, Andrew D. Frutkin.

Swain 23 Oct Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)

TARGET and TACTICS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for.

Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.

Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis David H. Adams et al (U.S. CoreValve Clinical Investigators) Journal Club November.

A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.

ProximAl pRotection with the MO.MA device dUring caRotid stenting proximAl pRotection with the MO.MA device dUring caRotid stenting Barry T. Katzen MD.

Baseline Characteristics Current or Former Smoker Diabetic Hypertension 25.7 Prior MI Prior Heart Failure.

The GOLIATH Study ..

Determination of the RAdial versus GrOiN coronary angioplasty The Result of DRAGON Trial Shigeru Saito, MD Department of Cardiology and Catheterization.

A Controlled Trial of Renal Denervation for Resistant Hypertension

UC c EN. Through Medtronic sponsored research, the Transcatheter Aortic Valves clinical portfolio is studying over 11,000 subjects at over 125.

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc

Martin B. Leon, MD on behalf of the PARTNER Investigators TCT 2010; Washington, DC; September 23, 2010 Transcatheter Aortic Valve Implantation in Inoperable.

A Prospective, Randomized Evaluation of Supersaturated Oxygen Therapy After Percutaneous Coronary Intervention in Acute Anterior Myocardial Infarction.

EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.

Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Trends in Vascular Complications After Diagnostic.

Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.

Impact of Anticoagulation Regimens on Sheath Management and Bleeding in Patients Undergoing Elective Percutaneous Coronary Intervention in the STEEPLE.

SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.

Dr. Quan, Dr. Mirhashemi, Dr. Chiang

Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology The EXERRT trial – “EXErcise to Regadenoson in Recovery.

Clinical Trial Design for Second Generation TAVI - Academic View

PFO FDA Considerations for Labeling and Future Trials

These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,

Update on the Watchman Device CRT 2010 Washington, DC

Table 1: Table 2: Non Therapeutic Angiograms in Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment Does not Adversely Affect Patient.

Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.

The CLOSER Trial: A Multicenter Study on the Clinical Safety and Effectiveness of Closer™ VSS, a Novel Resorbable Transfemoral Vascular Access Sealing.

Damian Gimpel Waikato Cardiothoracic Unit Journal Club

For the HORIZONS-AMI Investigators

Harmonized Assessment by Randomized Multicenter Study of OrbusNEich’s COMBO StEnt Japan-USA HARMONEE: Primary Report of A Randomized Trial of a Bioabsorbable.

Why Radial Access Should be the Default for Women undergoing PCI?

For the CLOSE-UP study group

Axel Linke University of Leipzig Heart Center, Leipzig, Germany

One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart.

PMA Analysis of the CREST Trial Approvability of the RX Acculink Carotid Stent System for Revascularization of Carotid Artery Stenosis in Standard Surgical.

Cardiovacular Research Technologies

Patented Technology to Seal Arterial Access Sites

Dabigatran in myocardial injury after noncardiac surgery

How and why this study may change my practice ?

For the HORIZONS-AMI Investigators

For the HORIZONS-AMI Investigators

ARNO TRIAL (Antithrombotic Regimens aNd Outcome)

% Heparin + GPI IIb/IIIa Bivalirudin +

An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48

BRAVO-3 Trial design: Patients undergoing transfemoral TAVR were randomized in a 1:1 fashion to bivalirudin or UFH. They were followed for 30 days. Results.

Complication rates following 4-Fr versus 6-Fr transfemoral vascular access – prospective audit at a single centre Chung R1, Weller A1, Bowles C1, Sedgwick.

Presentation transcript:

ECLIPSE Trial: Ensure’s Vascular Closure Device Speeds Hemostasis S. Chiu Wong MD Director, Cardiac Catheterization Laboratories New York Presbyterian Hosp.- Cornell Campus Professor of Medicine Weill Medical College of Cornell University SCAI / ACCi Late Breaking Trial April 2 nd Chicago, IL

ECLIPSE Trial Eclipse ® Closure Device The investigational ExoSeal  device (Cordis, Miami FL) is a novel 3rd generation 6 Fr. extra- vascular closure device with a painless deployment mechanism that delivers a poly-glycolic acid (PGA) “felt-like” plug atop the femoral artery anchored by the neuro-vascular bundle sheath.

U.S. multicenter pivotal study comparing ExoSeal  and manual compression with 2:1 randomization was performed to assess the safety and efficacy of ExoSeal  in patients undergoing 6Fr. diagnostic and interventional coronary/peripheral procedures ECLIPSE Trial ECLIPSE Trial Design

Two primary effectiveness endpoints to be tested for superiority: –Time to hemostasis (TTH) –Time to ambulation (TTA) Primary safety endpoint to be tested for non- inferiority: –30-day combined rate of access site related complications including bleeding, infection, ischemia or injury requiring medical or surgical treatment ECLIPSE Trial Objectives

ECLIPSE Trial Patient Enrollment ExoSeal ® 6F VCD (17 U.S. Sites) N = 488 Randomized N = 401 Roll-in N = 87 ExoSeal ® (N=267)Mannual Compression (n=134) Withdrawn N = 10 (7.5%) 30-day FU N=253 ( 94.8%) 30-day FU N=124 (92.5%) Withdrawn N = 14 (5.2%) Withdrawn N = 5 (2.7%) 30 day FU N = 82 (94.3%)

ECLIPSE Trial Results: Primary Effectiveness Endpoints Roll-in (N=87) ExoSeal ® (N=267) MC (N=134) p-value Procedure Success95.4%91.8%91.0% Device Success95.4%89.1%-- TTH (min.) 4.68    22.5 < TTA (hr.) 1.98    TT Eligibility for Hospital Discharge (hr.) 9.72    TT Hospital Discharge (hr.)    TT Device Deployment (min.) 0.94  

ECLIPSE Trial Results: Primary 30-Day Safety Endpoints Roll-in (N=87) ExoSeal ® (N=266) MC (N=134) Composite Major Adverse Event0.0% Vascular Repair0.0% Access Site Related Bleeding Requiring Transfusion 0.0% Access Site Related Infection Requiring Treatment 0.0% Any New Documented Ipsilateral Lower Extremity Ischemia 0.0% Surgery for Access Site-Related Nerve Injury 0.0%

In this multi-center randomized trial in pts following 6 Fr. diagnostic/interventional procedures, a significant reduction in the TTH and TTA (primary effectiveness endpoints) was achieved in pts treated with the investigational ExoSeal  device compared with MC Device deployment was achieved promptly in about 1 minute on average following procedure There was no difference in procedural success rates in both the ExoSeal ® and MC groups Remarkably, there were no 30-day combined access site related complications (primary safety endpoint) reported in either treatment cohort Exoseal  is non-inferior to MC in composite major adverse event at the pre-specified 4% margin level Exoseal ® compares favorably to manual compression for arteriotomy site management post 6 Fr. invasive/interventional procedures. ECLIPSE Trial Conclusions